-+ 0.00%
-+ 0.00%
-+ 0.00%

Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031

PUBT·06/22/2026 20:07:58
Listen to the news
Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031
  • Adaptive Biotechnologies priced an upsized private offering of USD 300 million 0% convertible senior notes due 2031, raised from USD 250 million.
  • Settlement is scheduled for June 22, 2026; initial purchasers hold an option to buy up to an additional USD 45 million of notes.
  • Net proceeds estimated at about USD 290.8 million, or about USD 334.5 million if the option is fully exercised.
  • Proceeds earmarked to repay the OrbiMed Purchase Agreement, fund a capped call, repurchase USD 25 million of stock, support MRD initiatives.
  • Initial conversion price set at about USD 24.11 per share; capped call cap price set at USD 34.44.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-277516), on June 22, 2026, and is solely responsible for the information contained therein.